CY1118434T1 - Φαρμακευτικη συνθεση αργης αποδεσμευσης κατασκευασμενη απο μικροσωματιδια - Google Patents

Φαρμακευτικη συνθεση αργης αποδεσμευσης κατασκευασμενη απο μικροσωματιδια

Info

Publication number
CY1118434T1
CY1118434T1 CY20171100060T CY171100060T CY1118434T1 CY 1118434 T1 CY1118434 T1 CY 1118434T1 CY 20171100060 T CY20171100060 T CY 20171100060T CY 171100060 T CY171100060 T CY 171100060T CY 1118434 T1 CY1118434 T1 CY 1118434T1
Authority
CY
Cyprus
Prior art keywords
microns
pharmaceutical composition
microparticles
microsumption
active substance
Prior art date
Application number
CY20171100060T
Other languages
English (en)
Inventor
Bertrand Ducrey
Patrick Garrouste
Catherine Curdy
Marie-Anne Bardet
Hervé Porchet
Eija Lundstrom
Frédéric Heimgartner
Original Assignee
Debiopharm Research & Manufacturing Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118434(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debiopharm Research & Manufacturing Sa filed Critical Debiopharm Research & Manufacturing Sa
Publication of CY1118434T1 publication Critical patent/CY1118434T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Φαρμακευτική σύνθεση κατασκευασμένη από μικροσωματίδια για την αργή αποδέσμευση μίας δραστικής ουσίας τουλάχιστον κατά τη διάρκεια μίας περιόδου που καλύπτει τον 6° μήνα μετά την ένεση της προαναφερθείσας σύνθεσης, όπου η προαναφερθείσα σύνθεση περιλαμβάνει μία ομάδα μικροσωματιδίων κατασκευασμένα από ένα συμπολυμερές του τύπου PLGA το οποίο ενσωματώνει μία δραστική ουσία στη μορφή ενός αδιάλυτου στο νερό άλατος πεπτιδίου• όπου το προαναφερθέν συμπολυμερές περαιτέρω περιλαμβάνει τουλάχιστον 75% γαλακτικό οξύ και εσωτερικό ιξώδες μεταξύ 0,1 και 0,9 dl/g, όπως μετριέται σε χλωροφόρμιο σε 25 °C και σε συγκέντρωση πολυμερούς 0,5 g/dL• όπου τα προαναφερθέντα μικροσωματίδια περαιτέρω έχουν κατανομή μεγέθους που ορίζεται ως ακολούθως: - το D (v,0,1) είναι μεταξύ 10 και 30 μικρομέτρων, - το D (v,0,5) είναι μεταξύ 30 και 70 μικρομέτρων, - το D (v,0,9) είναι μεταξύ 50 και 110 μικρομέτρων.
CY20171100060T 2007-06-06 2017-01-17 Φαρμακευτικη συνθεση αργης αποδεσμευσης κατασκευασμενη απο μικροσωματιδια CY1118434T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07109767 2007-06-06
IB2007054372 2007-10-27
PCT/IB2008/052241 WO2008149320A2 (en) 2007-06-06 2008-06-06 Slow release pharmaceutical composition made of microparticles
EP08763237.8A EP2164467B1 (en) 2007-06-06 2008-06-06 Slow release pharmaceutical composition made of microparticles

Publications (1)

Publication Number Publication Date
CY1118434T1 true CY1118434T1 (el) 2017-06-28

Family

ID=40032512

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100060T CY1118434T1 (el) 2007-06-06 2017-01-17 Φαρμακευτικη συνθεση αργης αποδεσμευσης κατασκευασμενη απο μικροσωματιδια
CY181101171T CY1120891T1 (el) 2007-06-06 2018-11-07 Φαρμακευτικη συνθεση αργης αποδεσμευσης κατασκευασμενη απο μικροσωματιδια

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY181101171T CY1120891T1 (el) 2007-06-06 2018-11-07 Φαρμακευτικη συνθεση αργης αποδεσμευσης κατασκευασμενη απο μικροσωματιδια

Country Status (32)

Country Link
US (3) US10166181B2 (el)
EP (3) EP3431077A1 (el)
JP (1) JP5419169B2 (el)
KR (1) KR101631475B1 (el)
CN (1) CN101677959B (el)
AP (1) AP3000A (el)
AU (1) AU2008259411B2 (el)
BR (1) BRPI0812250B8 (el)
CA (1) CA2688478C (el)
CO (1) CO6251234A2 (el)
CY (2) CY1118434T1 (el)
DK (2) DK2500014T3 (el)
EA (1) EA019284B1 (el)
ES (2) ES2694401T3 (el)
HK (1) HK1141737A1 (el)
HR (2) HRP20161785T1 (el)
HU (2) HUE040391T2 (el)
IL (1) IL202501A (el)
LT (2) LT2500014T (el)
MA (1) MA31422B1 (el)
ME (1) ME00959B (el)
MX (1) MX2009012856A (el)
MY (1) MY150450A (el)
NZ (1) NZ582423A (el)
PL (2) PL2164467T3 (el)
PT (2) PT2500014T (el)
RS (2) RS55591B1 (el)
SI (2) SI2500014T1 (el)
TN (1) TN2009000476A1 (el)
UA (1) UA99830C2 (el)
WO (1) WO2008149320A2 (el)
ZA (1) ZA200907940B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99830C2 (uk) 2007-06-06 2012-10-10 Дебио Ресшерчи Фармасютикю С.А. Фармацевтична композиція з пролонгованим вивільненням, виготовлена з мікрочастинок
PT105270B (pt) 2010-08-26 2012-05-31 Domino Ind Ceramicas S A Camada de sílica com libertação lenta de fragrância, telha cerâmica e respectivo processo de produção
CN105267153B (zh) * 2015-11-27 2018-05-11 上海苏豪逸明制药有限公司 一种曲普瑞林缓释微粒及其制备方法
CN105797134B (zh) * 2016-03-29 2019-06-14 浙江圣兆药物科技股份有限公司 一种难溶亮丙瑞林缓释制剂
EP3535297B1 (en) 2016-11-02 2022-08-10 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
KR102402639B1 (ko) 2017-11-24 2022-05-26 삼성전자주식회사 전자 장치 및 그의 통신 방법
CN111000798B (zh) * 2019-12-26 2021-11-23 四川恒博生物科技有限公司 一种采用原位凝胶技术的犬用非手术去势注射液
IT202000017191A1 (it) 2020-07-15 2022-01-15 Xbrane Biopharma Ab Procedimento senza acqua per preparare una composizione farmaceutica per un rilascio più prolungato e controllato di triptorelina o di un suo sale

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE61935T1 (de) 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
CH679207A5 (el) * 1989-07-28 1992-01-15 Debiopharm Sa
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
ATE223702T1 (de) * 1993-10-22 2002-09-15 Genentech Inc Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
US5945128A (en) * 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
MY118835A (en) 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
US6573238B2 (en) * 1997-11-07 2003-06-03 Chiron Corporation Method for producing sustained-release formulations
TW200800298A (en) * 2000-01-27 2008-01-01 Zentaris Ag Compressed microparticles for dry injection
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
BRPI0213226B1 (pt) * 2001-10-10 2016-03-01 Pf Medicament processo de preparação de uma composição farmacêutica sob forma de microesferas com liberação prolongada de um princípio ativo hidrossolúvel, e, microesferas
CA2523830A1 (en) * 2003-04-30 2004-11-11 Debiopharm S.A. Methods and compositions using gonadotropin hormone releasing hormone
KR100466637B1 (ko) * 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
FR2865938B1 (fr) * 2004-02-05 2006-06-02 Sod Conseils Rech Applic Formulation retard solide comprenant de l'acetate de triptoreline
KR101245919B1 (ko) 2005-12-22 2013-03-20 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드중합체를 포함하는 서방형 제제
UA99830C2 (uk) 2007-06-06 2012-10-10 Дебио Ресшерчи Фармасютикю С.А. Фармацевтична композиція з пролонгованим вивільненням, виготовлена з мікрочастинок

Also Published As

Publication number Publication date
PL2164467T3 (pl) 2017-07-31
ZA200907940B (en) 2010-08-25
RS55591B1 (sr) 2017-06-30
NZ582423A (en) 2011-10-28
CY1120891T1 (el) 2019-12-11
UA99830C2 (uk) 2012-10-10
WO2008149320A2 (en) 2008-12-11
WO2008149320A3 (en) 2009-02-05
KR20100023950A (ko) 2010-03-04
EP2500014A3 (en) 2012-11-07
KR101631475B1 (ko) 2016-06-20
AP2009005088A0 (en) 2009-12-31
AU2008259411B2 (en) 2013-10-17
EP3431077A1 (en) 2019-01-23
PT2164467T (pt) 2017-01-13
MY150450A (en) 2014-01-30
EP2164467A2 (en) 2010-03-24
AP3000A (en) 2014-10-31
BRPI0812250B8 (pt) 2021-05-25
CO6251234A2 (es) 2011-02-21
SI2500014T1 (sl) 2019-02-28
BRPI0812250A2 (pt) 2014-12-23
CN101677959A (zh) 2010-03-24
EP2164467B1 (en) 2016-12-14
LT2500014T (lt) 2019-01-25
EP2500014A2 (en) 2012-09-19
LT2164467T (lt) 2017-01-25
RS58248B1 (sr) 2019-03-29
JP5419169B2 (ja) 2014-02-19
CA2688478A1 (en) 2008-12-11
BRPI0812250B1 (pt) 2020-03-03
ES2611020T3 (es) 2017-05-04
DK2500014T3 (en) 2018-12-03
HUE031550T2 (en) 2017-07-28
AU2008259411A1 (en) 2008-12-11
US20110052717A1 (en) 2011-03-03
HK1141737A1 (en) 2010-11-19
PL2500014T3 (pl) 2019-04-30
EA019284B1 (ru) 2014-02-28
MX2009012856A (es) 2009-12-15
HRP20161785T1 (hr) 2017-03-10
TN2009000476A1 (en) 2011-03-31
ME00959B (me) 2012-06-20
PT2500014T (pt) 2018-11-21
IL202501A (en) 2015-11-30
EA200971132A1 (ru) 2010-04-30
US10166181B2 (en) 2019-01-01
US20230082575A1 (en) 2023-03-16
HUE040391T2 (hu) 2019-03-28
DK2164467T3 (en) 2017-01-30
EP2500014B1 (en) 2018-08-08
CN101677959B (zh) 2014-02-26
MA31422B1 (fr) 2010-06-01
SI2164467T1 (sl) 2017-05-31
IL202501A0 (en) 2010-06-30
CA2688478C (en) 2015-10-27
ES2694401T3 (es) 2018-12-20
JP2010529106A (ja) 2010-08-26
HRP20181854T1 (hr) 2019-02-08
US20190192423A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
CY1118434T1 (el) Φαρμακευτικη συνθεση αργης αποδεσμευσης κατασκευασμενη απο μικροσωματιδια
US20210290829A1 (en) Silk fibroin-based microneedles and methods of making the same
Raza et al. A review on recent advances in stabilizing peptides/proteins upon fabrication in hydrogels from biodegradable polymers
RU2011103437A (ru) Фармацевтическая композиция, содержащая микрочастицы с поверхностным покрытием
Tahmasbi Rad et al. Conducting scaffolds for liver tissue engineering
BR0312887A (pt) Forma de dosagem farmacêutica de múltiplos componentes
Tomar et al. In vivo evaluation of a conjugated poly (lactide-ethylene glycol) nanoparticle depot formulation for prolonged insulin delivery in the diabetic rabbit model
CY1117964T1 (el) Αντιψυχωτικη ενεσιμη συνθεση μακρας διαρκειας δρασης τεχνικος τομεας
CY1116196T1 (el) Ρευστη συνθεση περιλαμβανουσα βιοσυμβατες συνθεσεις ολιγομερους-πολυμερους
ES2422681T3 (es) Formulación de fármaco de moléculas pequeñas de liberación prolongada
JP2019502520A (ja) 薬剤放出デバイス及び使用
Lee et al. Subcutaneous vaccination using injectable biodegradable hydrogels for long-term immune response
JP2010518086A5 (el)
Stephansen et al. Interactions between surfactants in solution and electrospun protein Fibers: Effects on release behavior and fiber properties
Cui et al. Strategy of “block blends” to generate polymeric thermogels versus that of one-component block copolymer
WO2008081829A1 (ja) 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
Wang et al. Preliminary assessment of the safety evaluation of novel pH-sensitive hydrogel
Senarat et al. Levofloxacin HCl-incorporated zein-based solvent removal phase inversion in situ forming gel for periodontitis treatment
Sharma et al. Nefopam hydrochloride loaded microspheres for post-operative pain management: synthesis, physicochemical characterization and in-vivo evaluation
CY1121470T1 (el) Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης
BRPI0917819B8 (pt) compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado
Negi et al. Co-Delivery of Aceclofenac and Methotrexate Nanoparticles Presents an Effective Treatment for Rheumatoid Arthritis
김재원 et al. 1P-206 Preparation of UV-Curable Gelatin Derivatives for Injectable Particles
김신웅 et al. Preparation of UV-curable Chitosan Derivative Particles for Improving Drug Delivery Efficiency
Shen et al. Polymer applications in drug delivery